210 Participants Needed

Relational Agent for Cancer Risk

EH
JC
Overseen ByJulie Chapman-Greene, PhD, MPH
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Anita Y. Kinney, PhD, RN
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new method for assessing cancer risk using a chatbot called a Relational Agent (RA). It helps individuals in primary care settings understand their risk for hereditary cancer and guides them to genetic counseling if necessary. The study aims to determine how many people are identified as high risk and how many proceed to genetic counseling or testing. Participants should have received care at Rutgers Health and have internet access to engage with the chatbot. As an unphased trial, this study provides a unique opportunity to contribute to innovative cancer risk assessment methods.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that this Relational Agent is safe for cancer risk assessment?

Research has shown mixed safety results when using artificial intelligence chatbots in healthcare, such as those assessing cancer risk. Some studies found that these chatbots sometimes give incorrect advice. For instance, one study found that chatbots ordered unnecessary lab tests in 91.9% of cases and prescribed potentially harmful medications in 57.8% of cases. Another study showed that chatbots provided incorrect cancer treatment advice 33.33% of the time.

While these findings are concerning, this trial uses the Relational Agent, Alex, for risk assessment and genetic education, not for making medical decisions or giving treatment advice. The chatbot's role is primarily to collect information and assist users in learning. Therefore, even though chatbots might have issues in other contexts, their use in this trial is less likely to pose direct health risks. However, discussing any concerns with healthcare providers before joining a clinical trial is always advisable.12345

Why are researchers excited about this trial?

Unlike the standard of care for assessing cancer risk, which often involves genetic testing or medical imaging, the Relational Agent (RA) Alex stands out by using an AI-powered chatbot to interact with patients. This innovative approach engages users in personalized conversations, potentially increasing patient understanding and involvement in their health management. Researchers are excited because Alex offers a unique, accessible way to communicate complex health information, which could lead to better patient adherence and outcomes without the need for traditional medical appointments.

What evidence suggests that this Relational Agent is effective for cancer risk assessment?

This trial will evaluate the feasibility and acceptability of the Relational Agent (RA) Alex, a chatbot designed to identify patients at high risk for hereditary cancer syndromes. Studies have shown that chatbots like RA Alex effectively assist people in completing genetic cancer risk assessments, with about 36.7% of users finishing the process. These chatbots engage users and enhance their understanding of genetic risks, potentially leading to better follow-up actions such as genetic counseling. Although researchers continue to collect more data, these early findings suggest that chatbots can be a helpful tool in assessing cancer risk.678910

Who Is on the Research Team?

AY

Anita Y Kinney, PhD, RN

Principal Investigator

Rutgers, The State University of New Jersey

Are You a Good Fit for This Trial?

Project CARE is for patients at Rutgers Health primary care sites who may be at high risk for hereditary cancer. Participants will use a chatbot named Alex for cancer risk assessment and education. High-risk individuals will have the option of genetic counseling and testing.

Inclusion Criteria

Able to read and speak English
Receiving health care in Family Medicine or General Internal Medicine at Rutgers Health within the past 2 years
Have internet access (via smartphone, tablet, or computer)
See 3 more

Exclusion Criteria

Opted out of research participation in EPIC
I have undergone genetic testing for cancer risk.
Dementia (e.g., Alzheimer's disease) as indicated in EPIC
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Risk Assessment

Participants engage with a Relational Agent (RA, chatbot) for cancer risk assessment and genetic education

Up to 3 months
Digital engagement through patient portal

Genetic Counseling and Testing

High-risk participants are offered genetic counseling and testing

4 months

Follow-up

Participants are monitored for retention and satisfaction with the risk assessment feature

12 months

What Are the Treatments Tested in This Trial?

Interventions

  • Relational Agent (RA) Alex
Trial Overview The study tests a proactive outreach model using a digital Relational Agent (chatbot) to assess hereditary cancer risks in primary care settings. It measures how many people are identified as high-risk and how many pursue further genetic counseling or testing.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Feasibility and Acceptability of Relational Agent ChatbotExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Anita Y. Kinney, PhD, RN

Lead Sponsor

Citations

Addressing Genomic Disparities in Cancer SurvivorsThe study will: Test the effectiveness of a chatbot intervention (also called relational agent, or RA) vs. enhanced usual care (EUC) on engagement in genetic ...
Chatbots in Cancer Applications, Advantages and ...This state-of-the-art review article seeks to present both the benefits and the drawbacks of chatbots in the context of medicine and cancer.
Chatbot Artificial Intelligence for Genetic Cancer Risk ...The pooled estimated completion rate for the genetic cancer risk assessment portion of the chatbot was 36.7%. Although data were limited, ...
Hereditary Cancer Risk Using a Genetic Chatbot Before...A chatbot digital health tool can help identify patients at high risk for hereditary cancer syndromes before routine care appointments.
Evaluating a Chatbot as a Companion for Patients With Breast ...Objective: This study aims to evaluate the potential of an artificial intelligence–driven chatbot, specifically leveraging ChatGPT (GPT-4; ...
Medical accuracy of artificial intelligence chatbots in oncologyArtificial intelligence chatbots are promising but untested tools in oncology that may enhance clinical decision support.
Chatbot for Health Care and Oncology Applications Using ...The web-based chatbot. ItRuns (ItRunsInMyFamily) gathers family history information at the population level to determine the risk of hereditary ...
Rewards, risks with AI chatbots in chronic disease careThe chatbot also ordered unnecessary lab tests in 91.9% of the cases and prescribed potentially inappropriate or harmful medications to 57.8% ...
AI chatbot provides incorrect cancer treatment ...Researchers evaluate the reliability of large language models (LLMs) in providing cancer treatment recommendations, finding that 33.33% of ...
As cancer patients use AI chatbots, dangers lurk—but new ...Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security